The USA is the Major market when dispensing starts, we have most of the sick. Agreed 10 employees with only 1 CRO guy starting in Sept as CMO and 1 at SA Board. Nrx also top heavy too, IMO. I'd love to see their financials to gain a deeper understanding of compensation expense, but they certainly have a STACKED team that is extremely valuable for navigating FDA, government, big pharma, etc. Seems like money well spent if you can pull off a blockbuster drug or two. Development/cost$/logistics(?) of RLF-100 IV will be handled by RLF That's all being done through the manufacturing and distribution partnerships (edited)... the partnership agreement states that Neuro & Relief split PROFITS not revenues. I dont see where/how RLF fits into the new scheme of NRX/NYSE Bio co. It seems to me that they don't HAVE to fit in that scheme, but they could if GEM and all decide its best. But I see your point.
All eggs in the 102 patient review and not even talk of completing the first part of the IV 2B Trial, and nothing on amount of patients needed to reach statistical significance with the Phase 3 part. Seeing the last FDA update on approvals seems to show Full Data is King/Queen/Game or dont apply, IMO. Huge amount of 'Hope' for FDA EUA, general approvals on the 102. Guess Dr JJ/NRX feels no need for further plans. Kept pushing the 21 data. One of the slides on today's presentation showed a P<=.0001, so how much more certainty do they need for EUA? By the time we get EUA, I think there will be more discussion about full FDA approval. Also, there is more data they have on the open label trial.
EOD volume at SIX/here ? anyone have an opinion besides me. Price after this news. Creep up some, creep down some until EAU or full FDA approval
News 
Market Data 
Discover 
